OncoMed Announces Abstracts Accepted at the 2014 ASCO Annual Meeting

OncoMed Announces Abstracts Accepted at the 2014 ASCO Annual Meeting

REDWOOD CITY, Calif., April 23, 2014 (GLOBE NEWSWIRE) -- OncoMed
Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel
therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells,
today announced that several abstracts have been accepted for presentation at
the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting
being held May 30 – June 3, 2014 in Chicago, IL.

OncoMed will present new clinical data from its ongoing studies, including the
Phase 1b study of demcizumab (OMP-21M18, anti-DLL4) in non-small cell lung
cancer (NSCLC), the Phase 1/2 PINNACLE trial of OMP-59R5 (anti-Notch 2/3) in
small-cell lung cancer (SCLC) and the Phase 1 trial of OMP-54F28 (FZD8-Fc) in
patients with advanced solid tumors.The list of abstracts and timing of the
presentations is provided below.

Oral Presentation

  *A first-in-human Phase 1 study of anti-cancer stem cell agent OMP-54F28
    (FZD8-Fc), decoy receptor for WNT ligands, in patients with advanced solid
    tumors. (Abstract# 2505)

  Presenting author:Antonio Jimeno M.D., Ph.D., University of Colorado Cancer

  Date and time: Saturday, May 31, 2014 at 1:15 PM – 4:15 PM CDT

  Session: Oral Abstract Session - Developmental Therapeutics - Clinical
  Pharmacology and Experimental Therapeutics


  *Phase 1b of anti-cancer stem cell antibody OMP-59R5 (anti-Notch2/3) in
    combination with etoposide and cisplatin (EP) in patients (pts) with
    untreated extensive-stage small-cell lung cancer (ED-SCLC).(Abstract#

  Presenting author: David R. Spigel, M.D., Sarah Cannon Research Institute

  Date and time: Saturday, May 31, 2014 at 1:15 PM – 5:00 PM CDT

  Session: General Poster Session - Lung Cancer - Non-small Cell
  Local-regional/Small Cell/Other Thoracic Cancers

  *A Phase 1b study of the anti-cancer stem cell agent demcizumab (DEM),
    pemetrexed (PEM), and carboplatin (CARBO) in pts with first-line
    nonsquamous NSCLC. (Abstract # 2544)

  Presenting author: Mark McKeage, MBChB, MMedSc, Ph.D., FRACP, University of

  Date and time: Sunday, June 1, 2014 at 8:00 am – 11:45 am CDT

  Session: General Poster Session - Developmental Therapeutics - Clinical
  Pharmacology and Experimental Therapeutics

About Cancer Stem Cells

Cancer stem cells, or CSCs, are the subpopulation of cells in a tumor
responsible for driving growth and metastasis of the tumor. Also known as
tumor-initiating cells, CSCs have the capacity to divide and give rise to new
cancer stem cells via a process called self-renewal and to differentiate or
change into the other cells that form the bulk of the tumor. Common cancer
drugs target bulk tumor cells but have limited impact on CSCs, thereby
providing a path for recurrence of the tumor. OncoMed's product candidates
target CSCs by blocking self-renewal and driving differentiation of CSCs
toward a non-tumorigenic state, and also impact bulk tumor cells. OncoMed
believes its product candidates are distinct from the current generations of
chemotherapies and targeted therapies, and have the potential to significantly
impact cancer treatment and the clinical outcome of patients with cancer.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and
developing novel therapeutics targeting cancer stem cells (CSCs). OncoMed has
five anti-cancer product candidates in clinical development, including
demcizumab (anti-DLL4, OMP-21M18), OMP-59R5 (anti-Notch2/3), OMP-52M51
(anti-Notch1), vantictumab (anti-Fzd7, OMP-18R5), and OMP-54F28 (Fzd8-Fc),
which target key cancer stem cell signaling pathways including Notch and Wnt.
OncoMed has two other antibodies in preclinical development, OMP-305B83
(Anti-DLL4/Anti-VEGF bispecific) and Anti-RSPO3, with Investigational New Drug
filings planned for late 2014 or early 2015. OncoMed is also pursuing
discovery of additional novel anti-CSC product candidates.OncoMed has formed
strategic alliances with Celgene Corporation, Bayer Pharma AG and
GlaxoSmithKline (GSK). Additional information can be found at the company's
website: www.oncomed.com.

CONTACT: Investor Contact:
         OncoMed Pharmaceuticals
         Shari Annes
         Investor Relations
         (650) 888-0902
         Media Inquiries:
         BCC Partners
         Karen L. Bergman or
         Michelle Corral
         (650) 575-1509 or (415) 794-8662
         kbergman@bccpartners.com or

OncoMed Pharmaceuticals, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.